Serum Albumin-to-Creatinine Ratio as a Novel and Cost-Effective Biomarker for Silent Cerebral Infarction: A Retrospective Cohort Study

Mustafa Mazıcan^1*Ismail Karluka^1,2*

• ¹Department of Interventional Radiology, Division of Cerebrovascular Disease and Stroke, Başkent University Adana Dr. Turgut Noyan Application and Research Center, 01250,Adana, Turkey, Adana, Türkiye
• ²Faculty of Medicine, Başkent University, Ankara, Türkiye

This manuscript fits well within the scope of Frontiers in Neurology -Neurological Biomarkers as it investigates the prognostic role of the serum albumin-to-creatinine ratio (ACR) in relation to silent cerebral infarction and long-term neurological outcomes. By focusing on a cost-effective, accessible laboratory biomarker, our study provides clinically relevant insights into subclinical cerebrovascular pathology. The research highlights how ACR, a routinely measured serum parameter, may serve as a novel surrogate marker reflecting endothelial dysfunction, inflammation, and microvascular injury-mechanisms central to silent brain infarcts and neurovascular risk stratification. This aligns directly with the section's emphasis on identifying, validating, and translating neurological biomarkers into clinical practice. The retrospective cohort design, coupled with radiological and clinical outcome data, strengthens the translational value of our findings. We believe this work will contribute meaningfully to the ongoing efforts to improve early risk detection and guide preventive neurology strategies through accessible biomarker-based approaches.